OXFORD, UK, May 12th, 2014

PharmaVentures is pleased to announce that it has been engaged by Tiziana Life Sciences, Plc. to provide independent valuation advice for assets acquired as part of it's successful admission onto London Stock Exchange's AIM in April 2014.

Tiziana Life Sciences, is a London, England based company founded in 2013 with a mission to discover and develop novel molecules that inhibit BCL3 - a gene that is involved in cell motility in metastatic cancers. There is a large unmet need for targeted therapeutics for late-stage breast cancer, which currently has very low survivability - more than 92% of Stage 4 / metastatic cancer patients die within 5 years of diagnosis.

Fintan Walton, CEO, PharmaVentures Ltd said:

"PharmaVentures is delighted to have conducted this critically important independent valuation for the second bio-pharmaceutical company this year to join the London Stock Exchange."

Over the past 22 years, PharmaVentures has acted as advisor to over 600 global pharmaceutical and biotechnology clients in valuations and transactions covering licensing, pharma mergers, acquisitions, divestments and joint venture activities for companies.